High TNF‑α and/or p38MAPK expression predicts a favourable prognosis in patients with T1N0M0 hepatocellular carcinoma: An immunohistochemical study Corrigendum in /10.3892/ol.2019.10781

Zhang,Mao; Hu,Jie; Li,Haoran; Zhang,Shun; Hu,Weiyu; Wu,Liqun; Han,Bing

doi:10.3892/ol.2019.10193

June-2019 Volume 17 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2019 Volume 17 Issue 6

Full Size Image

Article Open Access

High TNF‑α and/or p38MAPK expression predicts a favourable prognosis in patients with T1N0M0 hepatocellular carcinoma: An immunohistochemical study

Corrigendum in: /10.3892/ol.2019.10781

Authors:
- Mao Zhang
- Jie Hu
- Haoran Li
- Shun Zhang
- Weiyu Hu
- Liqun Wu
- Bing Han
View Affiliations / Copyright

Affiliations: Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of General Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410006, P.R. China

Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 4948-4956
|
Published online on: March 27, 2019

https://doi.org/10.3892/ol.2019.10193
Expand metrics +

Abstract

Tumour necrosis factor α (TNF‑α) and p38 mitogen‑activated protein kinase (p38MAPK) serve an important role in regulating tumour cell apoptosis. However, a limited number of studies have investigated the predictive value of both TNF‑α and p38MAPK in hepatocellular carcinoma (HCC). An integrated bioinformatics analysis was initially performed using two datasets available from the Oncomine™ database to determine the association between TNF‑α and/or p38MAPK expression and prognosis of patients with HCC. Subsequently, TNF‑α and p38MAPK expression in tissue samples from 83 patients with HCC classified as T1N0M0, using the Tumour‑Node‑Metastasis (TNM) staging system, was investigated using immunohistochemistry. The associations between clinicopathological characteristics and different TNF‑α and p38MAPK expression levels in HCC were investigated using the χ2 test. Kaplan‑Meier and Cox univariate/multivariate survival analyses were performed to explore the predictive significance of TNF‑α and/or p38MAPK expression in patients with HCC. Using the Oncomine™ database, it was revealed that TNF‑α and/or p38MAPK expression was not significantly associated with overall survival (OS) or disease‑free survival (DFS) rates; however, TNF‑α and p38MAPK expression levels were positively associated (P<0.05), and high p38MAPK expression was significantly associated with low aspartate aminotransferase levels (P<0.05). Compared with low expression levels of TNF‑α and p38MAPK together, high expression of TNF‑α alone, p38MAPK alone and TNF‑α and p38MAPK together were significantly associated with improved OS and DFS rates (P<0.05). Additionally, multivariate Cox regression models suggested that high expression levels of TNF‑α alone, p38MAPK alone, or TNF‑α and p38MAPK together in the HCC microenvironment were independent predictive factors for OS and DFS rates (P<0.05). Patients with T1N0M0 HCC with high TNF‑α and/or p38MAPK expression had a significantly lower risk of recurrence and mortality compared with patients with low TNF‑α and p38MAPK expression. Consequently, TNF‑α and p38MAPK could serve as predictive biomarkers or potential therapeutic targets for T1N0M0 HCC treatment.

View Figures

View References

1	Qin H, Du X, Zhang Y and Wang R: Platycodin D, a triterpenoid saponin from Platycodon grandiflorum, induces G2/M arrest and apoptosis in human hepatoma HepG2 cells by modulating the PI3K/Akt pathway. Tumor Biol. 35:1267–1274. 2014. View Article : Google Scholar
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 65:69–90. 2011. View Article : Google Scholar
3	Josep ML: Hepatocellular carcinoma. Lancet (London, England). 9399:2003.
4	Carr BI: Hepatocellular carcinoma: Current management and future trends. Gastroenterology. 127:S218–S224. 2004. View Article : Google Scholar : PubMed/NCBI
5	Altekruse SF, McGlynn KA, Dickie LA and Kleiner DE: Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology. 55:476–482. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg. 253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
7	Takayama T: Surgical treatment for hepatocellular carcinoma. Japanese J Clin Oncol. 41:447–454. 2011. View Article : Google Scholar
8	Poon RT: Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge. Hepatology. 54:757–759. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
10	Caminero A, Comabella M and Montalban X: Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: An ongoing story. J Neuroimmunol. 234:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
11	Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, et al: Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 5:828–831. 1999. View Article : Google Scholar : PubMed/NCBI
12	Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC and Ching LM: Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy. Cancer Res. 59:633–638. 1999.PubMed/NCBI
13	Mugami S, Dobkin-Bekman M, Rahamim-Ben Navi L and Naor Z: Differential roles of PKC isoforms (PKCs) in GnRH stimulation of MAPK phosphorylation in gonadotrope derived cells. Mol Cell Endocrinol. 463:97–105. 2018. View Article : Google Scholar : PubMed/NCBI
14	Yokota T and Wang Y: p38 MAP kinases in the heart. Gene. 575:369–376. 2016. View Article : Google Scholar : PubMed/NCBI
15	Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh Y: Induction of apoptosis by ASK1, a mammalian MAPKKK That activates SAPK/JNK and p38 signaling pathways. Science. 275:90–94. 1997. View Article : Google Scholar : PubMed/NCBI
16	Meldrum KK, Meldrum DR, Hile KL, Yerkes EB, Ayala A, Cain MP, Rink RC, Casale AJ and Kaefer MA: p38 MAPK mediates renal tubular cell TNF-alpha production and TNF-alpha-dependent apoptosis during simulated ischemia. Am J Physiol Cell physiol. 281:C563–C570. 2001. View Article : Google Scholar : PubMed/NCBI
17	Valladares A, Alvarez AM, Ventura JJ, Roncero C, Benito M and Porras A: p38 mitogen-activated protein kinase mediates tumor necrosis factor-alpha-induced apoptosis in rat fetal brown adipocytes. Endocrinology. 141:4383–4395. 2000. View Article : Google Scholar : PubMed/NCBI
18	Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
19	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
20	Kamarajah SK, Frankel TL, Sonnenday C, Cho CS and Nathan H: Critical evaluation of the American joint commission on cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC): A surveillance, epidemiology, end results (SEER) analysis. J Surg Oncol. 117:644–650. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zhang M, Zhang S, Yang Z, Hu J, Hu W, Sun P, Wu L and Han B: Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence. Oncol Lett. 16:7158–7165. 2018.PubMed/NCBI
22	Green S, Dobrjansky A and Chiasson MA: Murine tumor necrosis-inducing factor: Purification and effects on myelomonocytic leukemia cells. J Natl Cancer Inst. 68:997–1003. 1982.PubMed/NCBI
23	Matthews N and Watkins JF: Tumor-Necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br J Cancer. 38:302–309. 1978. View Article : Google Scholar : PubMed/NCBI
24	Mose M, Kang Z, Raaby L, Iversen L and Johansen C: TNFα-and IL-17A-mediated S100A8 expression is regulated by p38 MAPK. Exp Dermatol. 22:476–481. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wang Y, Wang W, Wang L, Wang X and Xia J: Regulatory mechanisms of interleukin-8 production induced by tumour necrosis factor-α in human hepatocellular carcinoma cells. J Cell Mol Med. 16:496–506. 2012. View Article : Google Scholar : PubMed/NCBI
26	Sabio G and Davis RJ: TNF and MAP kinase signaling pathways. Semin Immunol. 26:237–245. 2014. View Article : Google Scholar : PubMed/NCBI
27	Luo JL, Maeda S, Hsu LC, Yagita H and Karin M: Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 6:297–305. 2004. View Article : Google Scholar : PubMed/NCBI
28	Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461–466. 2004. View Article : Google Scholar : PubMed/NCBI
29	Donnahoo KK, Shames BD, Harken AH and Meldrum DR: Review article: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 162:196–203. 1999. View Article : Google Scholar : PubMed/NCBI
30	van Horssen R, Ten Hagen TL and Eggermont AM: TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist. 11:397–408. 2006. View Article : Google Scholar : PubMed/NCBI